CO-ATORIS 40mg / 10mg film-coated tablets medication leaflet

C10BA05 • atorvastatin + ezetimibe • Cardiovascular system | Lipid modifying agents, combinations | Combinations of various lipid modifying agents

The combination of atorvastatin and ezetimibe is used for the treatment of dyslipidemia, particularly in patients with primary or familial hypercholesterolemia. Atorvastatin is an HMG-CoA reductase inhibitor that reduces cholesterol synthesis in the liver, while ezetimibe inhibits cholesterol absorption in the intestine. Through their complementary actions, these medications significantly lower LDL cholesterol levels.

This combination is administered orally, usually once daily, with the dosage adjusted based on lipid levels and the patient's response to treatment. It is particularly indicated for patients who do not achieve lipid targets with statins alone or who require additional LDL cholesterol reduction.

Common side effects include headaches, fatigue, muscle pain, diarrhea, and nausea. In rare cases, severe adverse reactions such as rhabdomyolysis, hepatotoxicity, or pancreatitis may occur.

Patients taking this combination should undergo regular monitoring for liver function and lipid levels. The atorvastatin and ezetimibe combination provides an effective option for reducing cardiovascular risk, helping to prevent major cardiovascular events.